News
Analyst Ratings For Mirum Pharmaceuticals
17 Apr 24
Analyst Ratings
Stifel Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $48
17 Apr 24
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
2 Apr 24
News, Price Target, Analyst Ratings
Mirum Pharmaceuticals' LIVMARLI Receives Reimbursement Recommendation By Canada's CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
2 Apr 24
Biotech, News, General
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
28 Mar 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
18 Mar 24
Analyst Ratings
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $43
18 Mar 24
News, Price Target, Analyst Ratings
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
14 Mar 24
Analyst Color, Biotech, News, Health Care, Price Target, FDA, Analyst Ratings, Trading Ideas, General
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $58
14 Mar 24
News, Price Target, Analyst Ratings
Mirum Pharmaceuticals Says LIVMARLI Receives FDA Approval For Treatment Of Cholestatic Pruritus In Patients With Progressive Familial Intrahepatic Cholestasis
13 Mar 24
News, FDA
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $40
4 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $45
29 Feb 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $69
29 Feb 24
News, Price Target, Analyst Ratings
Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know
29 Feb 24
Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Mirum Pharmaceuticals: Q4 Earnings Insights
28 Feb 24
Earnings
Mirum Pharmaceuticals Q4 2023 GAAP EPS $(0.66) Misses $(0.24) Estimate, Sales $69.55M Beat $67.76M Estimate
28 Feb 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Preview: Mirum Pharmaceuticals's Earnings
27 Feb 24
Earnings
Press releases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Apr 24
Press Releases
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
2 Apr 24
Press Releases
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
News, Management, Press Releases
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
13 Mar 24
Press Releases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Press Releases
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
5 Mar 24
Press Releases
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI
29 Feb 24
Press Releases
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
28 Feb 24
Press Releases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9 Feb 24
Press Releases
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
5 Feb 24
Press Releases